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COVID-19 is a severe acute respiratory disease caused by SARS-CoV-2, a new recently
emerged sarbecovirus. This virus uses the human ACE2 enzyme as receptor for cell entry,
recognizing it with the receptor binding domain (RBD) of the S1 subunit of the viral spike
protein. We present the use of phage display to select anti-SARS-CoV-2 spike antibodies
from the human naïve antibody gene libraries HAL9/10 and subsequent identification of 309
unique fully human antibodies against S1. 17 antibodies are binding to the RBD, showing
inhibition of spike binding to cells expressing ACE2 as scFv-Fc and neutralize active SARS-
CoV-2 virus infection of VeroE6 cells. The antibody STE73-2E9 is showing neutralization of
active SARS-CoV-2 as IgG and is binding to the ACE2-RBD interface. Thus, universal libraries
from healthy human donors offer the advantage that antibodies can be generated quickly and
independent from the availability of material from recovering patients in a pandemic situation.
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In 2015, Menachery et al. presciently wrote: “Our work suggestsa potential risk of SARS-CoV re-emergence from virusescurrently circulating in bat populations”1. Four years later, a
novel coronavirus causing a severe pneumonia is causing a
worldwide pandemic and has been named severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2). The outbreak was
initially noticed in a sea food market in Wuhan, Hubei province
(China) at the end of 2019. The disease has been named COVID-
19 (coronavirus disease 2019) by the World Health Organization.
Genome sequencing shows high identity to bat coronaviruses
(CoV, in particular RaTG13), beta-CoV virus causing human
diseases like SARS and Middle East respiratory syndrome
(MERS), and, to a lesser extent, the seasonal CoV hCoV-OC43
and HCov-HKU12,3. The spike (S) protein of SARS-CoV-2,
as well as SARS-CoV, binds to the human zinc peptidase
angiotensin-converting enzyme 2 (ACE2), which is expressed on
numerous cells, including lung, heart, kidney, and intestine cells,
thus initiating virus entry into target cells. S protein consists of
the N-terminal S1 subunit, which includes the receptor-binding
domain (RBD), and the C-terminal S2 subunit, which is anchored
to the viral membrane and is required for trimerization of spike
itself and fusion of the virus and host membrane4–6. The host
enzyme furin cleaves the S protein between S1 and S2 during viral
formation and the membrane-bound host protease TMPRSS2 is
responsible for the proteolytic activation of the S2’ site, which is
necessary for conformational changes and viral entry7–10.
Antibodies against the spike protein of coronaviruses are
potential candidates for therapeutic development11. Antibodies
against the S1 subunit, especially against RBD, can potently neu-
tralize SARS-CoV and MERS12–14. Monoclonal human antibodies
against SARS-CoV are described to cross-react with SARS-CoV-2;
some of them are also able to neutralize SARS-CoV-215,16. Other
reports show how monoclonal antibodies against SARS-CoV-2
can be selected by rescreening memory B cells from a SARS
patient17, selected from COVID-19 patients by single B cell
PCR18,19 or using phage display20,21. Human recombinant anti-
bodies are successfully used for the treatment of other viral dis-
eases. The antibody mAb11422 and the three antibody cocktail
REGN-EB323 showed a good efficiency in clinical trials against
Ebola virus24. The antibody palivizumab is European Medicines
Agency (EMA)/Food and Drug Administration (FDA) approved
for treatment of a severe respiratory infection of infants caused by
the respiratory syncytial virus (RSV)25,26 and can be used as a
guideline to develop therapeutic antibodies against SARS-CoV-2.
Antibody phage display is a powerful tool to generate human
antibodies against infectious diseases27. We successfully used this
technology to develop in vivo protective antibodies against
Venezuelan encephalitis virus28, Western-equine encephalitis29,30,
Marburg virus31, and Ebola Sudan virus32.
In this work, we show the generation of human recombinant
antibodies against the spike proteins of SARS-CoV-2 from a
universal, human naïve antibody gene library that was con-
structed before the emergence of SARS-CoV-2. Several selected
scFv-Fc antibodies efficiently inhibit the binding of the spike
protein to ACE2-expressing cells and are blocking SARS-CoV-2
infection of VeroE6 cells. The best antibody in the IgG format is a
potential candidate for the clinical development of a passive
immunotherapy for therapeutic and prophylactic purposes.
Results
SARS CoV2 spike domains or subunits and human ACE2 were
produced in insect cells and mammalian cells. SARS-CoV-2
RBD-SD1 (aa319–591) according to Wrapp et al.33, S1 subunit
(aa14–694), S1-S2 (aa14–1208, with proline substitutions at
position 986 and 987 and “GSAS” substitution at the furin site,
residues 682–685), and extracellular domain of ACE2 receptor
were produced in insect cells using a plasmid-based baculovirus-
free system34 as well as in Expi293F cells. All antigens with
exception of S1-S2 were produced with human IgG1 Fc part,
murine IgG2a Fc part, or with 6xHis tag in both expression
systems. S1-S2 was only produced with 6xHis tag. The extra-
cellular domain of ACE2 was produced with human IgG1 Fc part
or mouse IgG2a in Expi293F cells and 6xHis tagged in insect cells.
The yields of all the produced proteins are given in Table 1. A
graphical overview of all the produced proteins is given in Sup-
plementary Fig. 1. The expressed proteins were analyzed by size
exclusion chromatography (SEC; Supplementary Fig. 2).
S1 as well as S1-S2 were more efficiently produced in insect
cells compared to Expi293F cells. RBD-SD1 was produced well in
both production systems. The binding of the produced spike
domains/proteins to ACE2 was validated by enzyme-linked
immunosorbent assay (ELISA) and flow cytometric analysis on
ACE2-positive cells (Table 1).
Antibodies were selected by phage display. Antibodies were
selected against SARS-CoV-2 spike S1 subunit in four panning
rounds in microtiter plates (MTPs). The following single-clone
screening was performed by antigen ELISA in 96-well MTPs,
using soluble monoclonal scFv produced in Escherichia coli.
Subsequently, DNA encoding for the binders was sequenced and
unique antibodies were recloned as scFv-Fc fusions.
In detail, three panning strategies were compared. In a first
approach (STE70), the lambda (HAL9) and kappa (HAL10)
Table 1 Antigen production.
High Five cells Expi293F cells
Yield Binding to ACE2
in ELISA
Binding to ACE2 on cells Yield Binding to ACE2
in ELISA
Binding to ACE2 on cells
RBD-hFc 90 mg/L Yes Yes 203 mg/L Yes Yes
RBD-mFc 48 mg/L Yes Yes 116 mg/L Yes Yes
RBD-His 92 mg/L Yes Yes 35 mg/L Yes Yes
S1-hFca 7 mg/L Yes Yes <1 mg/L No No
S1-hFc 50 mg/L Yes Yes <1 mg/L Weak Yes
S1-mFc 36 mg/L Yes Yes <1 mg/L Yes Yes
S1-His 15 mg/L Yes Yes <1 mg/L Weak No
S1-S2-His 8 mg/L Yes Yes <1 mg/L No No
Max. production yields of SARS-CoV-2 spike protein/domains in insect cells (High Five) and mammalian cells (Expi293F). Proteins with His-tag produced in High Five cells and S1-hFc were additionally
purified by SEC.
aWith Furin site.
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libraries were combined and the antigen S1-hFc (with furin site,
produced in High Five cells) was immobilized in phosphate-
buffered saline (PBS). Here only seven unique antibodies were
identified. In a second approach, the selection was performed
separately for HAL10 (STE72) and HAL9 (STE73) using S1-hFc
as antigen (with furin site, SEC purified, immobilized in
carbonate buffer). Here 90 unique antibodies were selected from
HAL10 and 209 from HAL9. In a third approach (STE77 and
STE78), S1-hFc produced in Expi293F cells was used (immobi-
lized in carbonate buffer). Here the panning resulted in only three
unique antibodies that were not further analyzed in inhibition
assays. An overview is given in Table 2.
The antibody subfamily distribution was analyzed and
compared to the subfamily distribution in the HAL9/10 library
and in vivo (Fig. 1). The phage display-selected antibodies mostly
originated from the main gene families VH1 and VH3. Only few
antibodies were found using VH4. In 96 of the 309 selected
antibodies (31%), the V-gene VH3-23 was used. The V-gene
distribution in the lambda light chains was similar to the
distribution in the original library. Only antibodies comprising
the V-gene VL6-57 were selected from the lambda library HAL10.
In antibodies selected from the kappa library, VK2 and VK4 were
underrepresented.
Anti-SARS-CoV-2 scFv-Fc were produced transiently in
mammalian cells. In the interest of rapid throughput to quickly
address the growing impact of the COVID-19 pandemic, only a
selection of the unique antibodies was chosen for production as
scFv-Fc and characterization. Antibodies with potential glycosy-
lation sites in the complementarity determining regions (CDRs),
identified by in silico analysis, were excluded. A total of 109 scFv-
Fc antibodies were produced in 5 mL culture scale, with yields
ranging from of 20 to 440 mg/L.
Antibodies inhibit the binding of spike to ACE2-positive cells
in the scFv-Fc format. To further select potential therapeutic
candidates, an inhibition assay was established using flow cyto-
metry of ACE2-positive cells, measuring competition of S1-S2
trimer binding by scFv-Fc antibodies. The entire spike protein
ectodomain was used for this inhibition assay for optimal
representation of the viral binding. In a first screening, the 109
scFv-Fc were tested at 1500 nM (molar ratio antibody: S1-S2
30:1). Seventeen antibodies with inhibition better than 75% were
selected for further analysis (Fig. 2A, Table 3, and Supplementary
Fig. 3). The complete V-gene sequences of these 17 antibodies are
given in Supplementary Fig. 4.
To further characterize these 17 antibodies, their inhibition
of ACE2 binding was assessed at concentrations from 1500 to
4.7 nM (from 30:1 to ~1:10 Ab:antigen molar ratio) with the same
flow cytometric assay (Fig. 2B and Table 3). Antibodies STE72-
8E1 and STE73-2E9 showed 50% inhibition of ACE2 binding at a
molar ratio of 0.8 antigen-binding sites per spike monomer. For
further validation of the direct RBD:ACE2 inhibition, we
performed the same assay using a RBD-mFc construct (Fig. 2C).
With the exception of two antibodies (STE72-1G5 and STE73-
6B10), all antibodies showed high inhibition of binding with
molar ratios of 0.3–0.6:1 for STE72-4E12, STE72-8A2, STE72-
8A6, STE73-2B2, STE73-2G8, and STE73-9G3.
The inhibition of the 17 antibodies was further validated on
human Calu-3 cells, which naturally express ACE29 using RBD-
mFc (Supplementary Fig. 5A) and S1-S2-His (Supplementary
Fig. 5B) showing a stronger inhibition on Calu-3 compared to the
transiently overexpressing ACE2-positive Expi293F cells. The
Expi293F system allowed an improved estimation of inhibition
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S1-S2 was directly labeled with a fluorophore and the signals were
not amplified in comparison to RBD with a murine Fc and a
fluorophore-labeled secondary antibody. Further, ACE2-expressing
Expi293F cells present a much higher amount of ACE2 receptor on
their surface compared to Calu-3, due to the CMV-mediated
expression (data not shown). Taken together, these data show that
all 17 inhibiting antibodies selected against S1 directly interfered
with RBD-ACE2 binding.
Determination of EC50 of the inhibiting antibodies to RBD,
S1, and S1-S2. The EC50 of the inhibiting scFv-Fc on RBD, S1
(without furin site), and S1-S2 spike was measured by ELISA. All
inhibiting antibodies bound the isolated RBD (Fig. 3), identifying
it as their target on the viral surface. Most of the inhibiting
antibodies showed a half-maximal binding in the subnanomolar
range for RBD. While STE72-2G4 showed subnanomolar EC50
values for RBD and S1, it was discarded due to noticeable cross-
reactivity to mFc. The EC50 on the S1-S2 spike trimer was
reduced for most of the antibodies, in comparison to the isolated
RBD or S1.
ScFv-Fc combinations show synergistic effects in inhibition
assays. Combinations of best-inhibiting scFv-Fc were tested in
the flow cytometric inhibition assay using 1500 nM antibody
and 50 nM S1-S2 spike (Supplementary Fig. 6). Some of the
combinations showed an increase of inhibition compared to the
same amount of individual antibodies.
Anti-RBD scFv-Fc neutralize active SARS-CoV-2. All 17 inhi-
biting scFv-Fc were screened in a cytopathic effect (CPE)-based
neutralization assay using 250 plaque‐forming units (pfu)/well
SARS-CoV-2 Münster/FI110320/1/2020 and 1 µg/mL (~10 nM)
scFv-Fc (Fig. 4A and Table 3) to select antibodies for further
characterization as IgG. VeroE6 cells showed pronounced CPE
characterized by rounding and detachment clearly visible in
phase-contrast microscopy upon SARS-CoV-2 infection within
4 days, while uninfected cells maintained an undisturbed con-
fluent monolayer. Virus inoculum preincubated with anti-RBD
antibodies led to decreased CPE in varying degrees quantified by
automated image analysis for cell confluence. The scFv-Fc format
allowed rapid production for neutralization testing and allowed
faster functional pre-screening. All 17 antibodies showed neu-
tralization in this assay. Figure 4B shows examples for strong
(STE73-6C8) and weak (STE73-2C2) neutralizing antibodies and
controls.
Binding, inhibition, and SARS-CoV-2 neutralization in the
IgG format. Eleven scFv-Fc showing a neutralization efficacy of
90% according to the CPE-based neutralization assay were con-
verted into the IgG format. First, their binding was analyzed by
titration ELISA on RBD, S1, and S1-S2 (Supplementary Fig. 7 and
Table 3). Three antibodies lost binding after conversion to IgG
(STE72-8A2, STE72-8A6, and STE73-6B10, data not shown),
others showed reduced binding of different degrees, while three
antibodies retained their binding (STE70-1E12, STE72-4E12, and
STE73-2E9). In the next step, the antibodies were tested in the
cell-based inhibition assay using S1-S2 (Fig. 5A) or RBD (Fig. 5B).
Here the inhibition was confirmed for STE73-2E9, -9G3, and
-2G8. STE72-1B6 showed inhibition of RBD comparable to the
latter antibodies, but its activity was almost absent on S1-S2, thus
it was not further considered.
Inhibiting IgGs are binding at the RBD–ACE2 interface. The
efficiently inhibiting IgGs STE73-2E9, STE73-2G8, and STE73-
9G3 were analyzed for their binding to various S1 subunit var-
iants harboring a panel of recently reported mutations in RBD
region and the D614G mutation. Three assays were employed:
(1) ELISA (Fig. 6A, B), (2) surface plasmon resonance (SPR)
(Fig. 6B), and (3) bScreen protein array (Fig. 6B) with S1 and/or
RBD-SD1 proteins from different sources. All three antibodies
lost binding to RBD mutations in the region aa483–486 directly at
the RBD–ACE2 interface, showing that mutations in that region
affect their epitope on the antigen. There were only minor dif-
ferences between different approaches, e.g., at positions aa439 and
aa476 for STE73-2E9. We then used this information to guide
and validate computational docking simulations followed by
atomistic molecular dynamics simulations according to protocols
developed and well established in our group35, obtaining three-
dimensional atomic models of the antibody–RBD interaction for
these three antibodies (Fig. 6C). The binding models of the three
antibodies to the spike ectodomain are shown in Supplementary
Fig. 8.
STE73-2E9 neutralize SARS-CoV-2 in the IgG format. As a
final step, STE73-2E9, -9G3, and -2G8 antibodies were analyzed
in a plaque assay using the patient isolate SARS-CoV-2 (Münster/
FI110320/1/2020) to determine their neutralization potency. Here
STE73-2E9 showed an IC50 of 0.43 nM, STE73-9G3 showed only
an IC50 of 1.9 nM, and the IC50 of STE73-2G8 was not deter-
minable as IgG in this assay (Fig. 7A). The IC50 of STE73-2E9
Fig. 1 Use of V region genes in human anti-SARS-CoV-2 antibodies.
Comparison of the distribution of V region gene subfamilies in the universal
HAL9/10 library50, the in vivo distribution of subfamilies82, and the
distribution of antibodies against S1 selected from HAL9/10. A Abundance
of VH, B Vκ, and C Vλ.
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was validated with a second plaque assay with ~150 pfu resulting
in an IC50 of 0.41 nM (Fig. 7B).
Analysis of STE73-2E9 cross-reactivity with other cor-
onaviruses. The neutralizing antibody STE73-2E9 was further
characterized by titration ELISA on SARS-CoV-2 spike recom-
binant constructs (Fig. 7C) and S1 subunits from different cor-
onaviruses (Fig. 7D) showing that STE73-2E9 is binding
specifically SARS-CoV-2 spike protein in the RBD region. The
specific binding to S1/RBD of SARS-CoV-2 was further con-
firmed by the bScreen protein array-binding analysis (data not
shown).
STE73-2E9 binds with nM affinity to RBD. The affinity of
STE73-2E9 was determined by SPR as 2 × 10−9 M for RBD-SD1
(Fig. 7E) and 9.25−10 M for the complete spike protein (Fig. 7F).
Aggregation behavior of STE73-2E9. The aggregation behavior
of biologicals is a key factor for therapeutic development. STE73-
2E9 shows no relevant aggregation under normal conditions
(pH 7.4, room temperature (RT) in PBS), heat stress conditions
(pH 7.4, 45 °C, 24 h in PBS), and pH stress (pH 3, 24 h, RT),
implicating that it has favourable general physicochemical
properties that are a prerequisite for the development into a
passive vaccine (Supplementary Fig. 9).
Discussion
For 130 years, antibodies in animal sera or convalescent human
plasma were successfully used for the treatment of infectious
diseases, starting with the work of Emil von Behring und Shi-
basaburo Kitasato against diphtheria35. However, the efficacy of
human plasma derived from convalescent donors depends on the
viral pathogen. In case of Ebola, the survival upon treatment with
Fig. 2 Inhibition of SARS-CoV-2 spike protein binding to cell (flow cytometry). A Inhibition prescreen of 109 scFv-Fc antibodies on ACE2-positive cells
using 1500 nM antibody and 50 nM spike protein (30:1 ratio). The antibodies selected for detailed analysis are marked in colors. Data show single
measurements. B IC50 determination by flow cytometry using 50 nM S1-S2 trimer and 4.7–1500 nM scFv-Fc. C IC50 determination by flow cytometry
using 10 nM RBD and 0.03–1000 nM scFv-Fc. The inhibition assays were made as single titrations. Logistic5 fit of Origin was used to determine the IC50.
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convalescent human plasma was not significantly improved over
the control group36. On the other hand, reduced mortality and
safety was shown for convalescent plasma transfer in case of
influenza A H1N1 in 200937,38. This approach was also used
against emerging coronaviruses. While the outcomes were not
significantly improved in a very limited number of MERS
patients39, the treatment was successful for SARS40,41. This
approach was also used for COVID-19 with promising results42.
The mode of action of these polyclonal antibody preparations
may vary, including virus neutralization, Fcγ receptor-binding-
mediated phagocytosis, or antibody-dependent cellular cytotoxi-
city (ADCC) as well as complement activation43–45. In any serum
therapy, the composition and efficacy of convalescent plasma is
expected to differ from donor to donor, as well as from batch to
batch, and sera must be carefully controlled for viral con-
taminations (e.g., HIV, hepatitis viruses) and neutralization
potency. A convalescent patient can provide 400–800 mL plasma,
with 250–300 mL of plasma typically needed per treatment. With
two rounds of treatment per patient, this is a grave limitation,
since one donor can only provide material for 1–2 patients42,43.
Human or humanized monoclonal antibodies are a powerful
alternative to polyclonal antibodies derived from convalescent
plasma. Following this approach, the humanized antibody Pali-
vizumab was approved in 2009 for treatment and prevention of
RSV infections46. Other antibodies against viral diseases suc-
cessfully tested in clinical studies are mAb114 and REGN-EB3
against Ebola disease24.
Phage display-derived antibodies are typically well-established
medications: 12 such antibodies are approved by EMA/FDA at
the time of writing, a significant increase compared to the six such
antibodies approved in 201647. In this work, we used phage
display to isolate monoclonal human antibodies capable of neu-
tralizing SARS-CoV-2 from a universal, naïve antibody gene
library that was generated from healthy donors before the
emergence of the SARS-CoV-2 virus. This allowed selection of
human antibodies against this virus without the necessity to
obtain material from COVID-19-infected individuals. While most
antibodies against SARS-CoV-2 were obtained from convalescent
patients with few exceptions20,21,48,49, our approach demonstrates
that human antibodies can be generated without the necessity to
wait for material from COVID-19-infected individuals. With
SARS-CoV-2, the whole world invested an unprecedented
amount of resources toward a single goal. This is not common for
other diseases and infective outbreaks. The fact that research
groups and companies were able to rapidly recruit many indivi-
duals and quickly find potentially good antibodies should not be
held as standard for every situation. Therefore, this strategy offers
a very fast additional opportunity to respond to future pandemics.
As the human receptor of SARS-CoV and SARS-CoV-2 is
ACE23, we focused on antibodies which directly block the
interaction of the spike protein with this receptor and antibodies
preventing ACE2 binding were shown to potently neutralize the
closely related SARS-CoV virus16. Three hundred and nine
unique fully human monoclonal antibodies were generated using
different panning strategies. The S1 subunit produced in insect
cells was better suited for antibody selection than the S1 subunit
produced in mammalian cells. The V-gene distribution of the
selected anti-Spike antibodies is largely in accordance with the V-
gene subfamily distribution shown by Kügler et al.50 for anti-
bodies selected against 121 other antigens from HAL9/10. Only
the VH1 subfamily was overrepresented and VH4 and
Vkappa4 subfamilies were rarely selected despite their presence in
the HAL libraries. The most frequently used V-gene was VH3-30.
Interestingly, an increased use of this V-gene in anti-SARS-CoV-
2 antibodies was also described by Robbiani et al.51 for anti-RBD
B cells selected from COVID-19 patients. By contrast, the second
most selected V-gene was VH3-53, which was selected in our
approach only once. Robbiani et al. also described an over-
represented use of VL6-57, as found in our antibodies as well.
However, it has to be noted that VL6 is also overrepresented in
our naïve library compared to its in vivo occurrence.
From the initial 309 scFv, 109 were recloned in the scFv-Fc
IgG-like bivalent format. Their ability to inhibit binding of
fluorescently labeled S1-S2 trimer to ACE2-expressing cells was
assessed by flow cytometry. The half-maximal inhibition of the
best inhibiting 17 scFv-Fc was measured both with the spike
Fig. 3 Determination of EC50 on RBD. Binding in titration ELISA of the 17 best inhibiting scFv-Fc on RBD (fusion protein with murine Fc part), S1 (fusion
protein with murine Fc part), or S1-S2 (fusion protein with His tag). Sequence SARS-CoV-2 (Gene bank QHD43416). An unrelated antibody with murine Fc
part (TUN219-2C1), human HEK293 cell lysate, BSA, or lysozyme were used as controls. Experiments were performed in duplicate and mean values are
given. EC50 were calculated with GraphPad Prism Version 6.1, fitting to a four-parameter logistic curve.
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trimer and isolated RBD. Significantly, some of the antibodies
showed half-maximal inhibition at a ratio around 1:1—in certain
cases even better—when calculated per individual binding site
(antigen-binding site:spike monomer/RBD). A similar molar ratio
of 1:1 was demonstrated by Miethe et al. for inhibition of botu-
linum toxin A52. In the trimeric spike protein, the RBD can be in
an “up” (open) or “down” (close) position. The “down” con-
formation cannot bind to ACE2, in contrast to the less stable “up”
conformation33. The RBDs can be in different conformations on
the same spike trimer, which offers a possible explanation for the
observed effective antibody to spike molar ratios lower than 1:1.
This is in accordance with the cryo-electron microscopic images
recorded by Walls et al.4, where they could find half of the
recorded trimers with one RBD in the open conformation. We
observed that molar ratios for half maximal inhibition were lower
for RBD compared to spike protein. For some antibodies,
approximately 0.5 antigen-binding sites were needed to achieve a
50% inhibition. The fact that the antibodies are more efficient at
inhibiting RBD binding to ACE2 rather than S1-S2 trimer
binding can be explained with the higher affinity of the antibodies
for the isolated RBD compared to the trimeric spike, which in
turn points to the presence of partially or completely inaccessible
epitopes on the trimer, an occurrence seen in other viruses. This
is similar to what was reported by Pinto et al.17, who also showed
a lower affinity of the antibody S309 for spike compared to RBD.
Inhibition of ACE2 binding was stronger on the human lung
cells Calu-3, which better represent the in vivo situation than
transiently ACE2-overexpressing cells. Nevertheless, we did the
titration assays on ACE2-overexpressing Expi293F cells because
these seemed to allow a better quantitative discrimination of
inhibiting potency.
Antibody combinations can have a synergistic effect as pre-
viously described for toxins and viruses32,53–55. This approach
may also avoid formation of viral escape mutants. Here the best
combinations showed a significantly improved inhibition efficacy,
at least when using an excess of antibodies (Ab:Ag molar
ratio 30:1).
All of the 17 scFv-Fc were tested in neutralization assays using
a SARS-CoV-2 strain isolated from a patient and all antibodies
showed a degree of neutralization in this assay. While this study
Fig. 4 SARS-CoV-2 neutralization in the scFv-Fc format. Neutralization analysis using 250 pfu of SARS-CoV-2 in a CPE-based neutralization assay. A Cell
monolayer occupancy at 4 days post infection in the absence of neutralizing antibodies was compared to uninfected control cells and median values were
normalized as 0 and 100% occupancy, respectively. Histograms indicate medians of normalized monolayer occupancy in a neutralization assay using 1 µg/
mL (~10 nM) antibody for each of the 17 tested antibodies. Data show the median from 4 or 6 replicates, the black dots indicate monolayer occupancy in
individual assays, and the range is given for the maximum and minimum measurements. B Representative phase-contrast microscopic pictures of
uninfected cells, cells infected in the absence of antibodies, in the presence of a poorly neutralizing scFv-Fc (STE73-2C2), or of a highly neutralizing scFv-Fc
(STE73-6C8).
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did not aim to define the lowest effective concentration of indi-
vidual antibodies in limiting dilution conditions, all tested anti-
bodies showed a clear and measurable effect at a relatively low
concentration. Therefore, our approach provided a rapid selection
of antiviral antibodies.
In a next step, we converted 11 antibodies with the best neu-
tralization efficacy according to the cytopathic assay into the IgG
format. It was completely unexpected that most antibodies lost
efficacy in the inhibition assay after conversion from scFv-Fc to
IgG including antibodies like STE70-1E12 without loss of affinity
according to the titration ELISA. These results are in contrast to
former results where none54 or only a low percentage55,56 of
antibodies lost efficacy after conversion from scFv-Fc to IgG.
Nevertheless, three antibodies showed a good inhibition in the
cell-based assay and did not bind to the region of aa483–486
known for RBD mutations from publications19,57 and from
GISAID database (www.gisaid.org). Experimentally validated
computational docking shows that these antibodies still at least
partially occupy the ACE2-binding site on the RBD, thus likely
achieving direct inhibition of virus–ACE2 interaction. The
binding sites of antibody BD368-218, B3858, and REGN1093359
also overlap with the RBD–ACE2 binding interface. The best
neutralizing antibody STE73-2E9 showed an IC50 of 0.41 nM,
which is higher compared to antibodies derived from COVID-19
patients. Cao et al.18 reported an IC50 of 33 ng/mL (~0.22 nM)
for BD368-2 in a comparable live virus plaque assay. Other
publications reports better IC50 efficacies, e.g., Kreye et al.60 for
CV07-209 with 3.1 ng/mL (~0.02 nM) or Rogers et al.61 for
CC6.33 with 1 ng/mL. Some assays are often not directly com-
parable, e.g. Rogers et al. used SARS-CoV-2 pseudovirus instead
of authentic virus.
The neutralizing antibody STE73-2E9 was specific for SARS-
CoV-2, and we conclude that this antibody is a suitable candidate
for the development of passive immunotherapy for the treatment
of COVID-19. It could be used not only therapeutically to prevent
individuals from being hospitalized in intensive care units but
also prophylactically to protect health care workers or risk groups
who do not respond to vaccination. Before clinical application,
the risk of antibody-dependent enhancement (ADE) of disease
has to be considered for COVID-19. In contrast to antibodies
against Ebola where ADCC is important for protection22, anti-
bodies directed against the spike protein of SARS-CoV-2 may
lead to ADE62–64. SARS cause an acute lung injury, which is also
driven by immune dysregulation and inflammation caused by
anti-spike antibodies65. While Quinlan et al.66 described that
animals immunized with RBD SARS-CoV-2 did not mediate
ADE and suggested for vaccines the use of RBD, some of the
monoclonal antibodies we analyzed in this study lead to an
increased binding of the spike protein to ACE2-positive cells. A
possible explanation could be multimerization of the spike by
Fig. 5 Inhibition of RBD–ACE2 interaction by IgG. A IC50 determination by flow cytometry using 50 nM S1-S2-His and 0.5-500 nM IgG. B IC50
determination by flow cytometry using 10 nM RBD-mFC and 0.1–100 nM IgG. Palivizumab was used as negative control. The inhibition assays were made
as single titrations. Logistic5 fit of Origin was used to determine the IC50.
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Fig. 6 Binding to RBD mutants, epitopes, and structure models. A ELISA using STE73-2E9, -9G3, and -2G8 on S1-His with different RBD mutations.
B Overview of the binding of STE73-2E9, -9G3, and -2G8 to different RBD mutations analyzed by ELISA, SPR, and protein array. Sequence SARS-CoV-2
(Gene bank QHD43416). ELISA experiments were performed in duplicate and mean values are given. C The three antibodies STE73-2E9, -9G3, and -2G8
are binding to the ACE–RBD interface (docking models based on epitope data from binding to RBD mutations). Experimentally validated computational
models of the variable regions of the antibodies (colored cartoons) binding to the RBD (white surface, same orientation in all images) are shown. The
cartoon representation of ACE2 is also shown for comparison.
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antibody “cross-linking” in this assay or the stabilization of an
infection-promoting conformation by the antibodies. These
aspects need to be carefully considered in any development of
therapeutic antibodies; we suggest to focus on RBD and/or the
use of silenced Fc parts with deleted Fcγ and C1q binding67–69 for
safety reasons.
In conclusion, we report the successful isolation and char-
acterization of a fully human, recombinant anti-spike neutralizing
monoclonal antibody from naïve phage display libraries. Our
approach demonstrates how neutralizing antibodies can be effi-
ciently selected in a rapid time frame and without the need of
convalescent patient material. Furthermore, the strategy we used
efficiently targeted the spike:ACE interface allowing the selection
of directly blocking antibodies.
Methods
Design of expression vectors. Production in Expi293F cells was performed using
pCSE2.5-His-XP, pCSE2.6-hFc-XP, or pCSE2.6-mFc-XP70 where the respective
single-chain variable fragment of the antibodies or antigens were inserted by NcoI/
NotI (NEB Biolabs) digestion. Antigen production in High Five insect cells was
performed using NcoI/NotI compatible variants of the OpiE2 plasmid71 containing
an N-terminal signal peptide of the mouse Ig heavy chain; the respective antigen;
and C-terminal 6xHis-tag, hFc, or mFc. Single point mutations in S1-HIS con-
structs were inserted through site-directed mutagenesis using overlapping primers
according to Zheng et al.72 with slight modifications: S7 fusion polymerase
(Mobidiag, Espoo, Finland) with the provided GC buffer and 3% dimethyl sulf-
oxide was used for the amplification reaction. The used olignucleotide primers for
cloning and site-directed mutagenesis are given in Supplementary Table 1.
Production of antigens in insect cells. Different domains or subunits of the spike
protein (GenBank: MN908947), S1 subunit mutants, and the extracellular domain
of ACE2 receptor (GenBank NM_021804.3) were baculovirus-free produced in
High Five cells (Thermo Fisher Scientific) by transient transfection as previously
described in Bleckmann et al.34. Briefly, High Five cells were cultivated at 27 °C,
110 rpm in ExCell405 media (Sigma) and kept at a cell density between 0.3 × 106
and 5.5 × 106 cells/mL. For transfection, cells were centrifuged and resuspended in
fresh media to a density of 4 × 106 cells/mL and transfected with 4 µg plasmid/mL
and 16 µg/mL of PEI 40 kDa (Polysciences). Four hours up to 24 h after trans-
fection, cells were fed with 75% of the transfection volume. At 48 h after trans-
fection, cell culture medium was doubled. Cell supernatant was harvested 5 days
after transfection in a two-step centrifugation (4 min at 180 × g and 20 min at above
3500 × g) and 0.2 µm filtered for purification.
Production of antigens and scFv-Fc in mammalian cells. Antibodies, different
domains, or subunits of the spike protein and the extracellular domain of ACE2
were produced in Expi293F cells (Thermo Fisher Scientific). Expi293F cells were
cultured at 37 °C, 110 rpm, and 5% CO2 in Gibco FreeStyle F17 expression media
(Thermo Fisher Scientific) supplemented with 8 mM Glutamine and 0.1% Pluronic
F68 (PAN Biotech). At the day of transfection, cell density was between 1.5 × 106
and 2 × 106 cells/mL and viability at least >90%. For formation of DNA:PEI
complexes, 1 µg DNA/mL transfection volume and 5 µg of 40 kDa PEI
Fig. 7 Characterization of the neutralizing antibody STE73-2E9 in IgG format. A Neutralization of 20–30 pfu SARS-CoV-2 by STE73-2E9, -9G3, and
-2G8. Palivizumab was used as isotype control. B Validation of neutralization potency of STE73-2E9 using 100 pfu. Neutralization assays were performed in
triplicates, mean ± s.e.m. are given. C Titration ELISA on the indicated antigens. ELISA shows single titration of two representative experiments (see also
Supplementary Fig. 7). D Cross-reactivity to other coronavirus spike proteins analzyed by ELISA. S1-HIS SARS-CoV-2 Hi5 was produced in house. S1-HIS
SARS-CoV-2 HEK and all other coronavirus S1 domain proteins were obtained commercially. ELISA experiments were performed in duplicate and the mean
values are given. E, F Kinetic parameter determination through single-cycle kinetic titration SPR of STE73-2E9 IgG on HEK cell produced RBD-SD1 and S1-
S2, respectively (concentrations: 200, 100, 50, 25, 12.5, 6.25 nM).
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(Polysciences) were first diluted separately in 5% transfection volume in supple-
mented F17 media. DNA and PEI was then mixed and incubated ~25 min at RT
before addition to the cells. Forty-eight hours later, the culture volume was doubled
by feeding HyClone SFM4Transfx-293 media (GE Healthcare) supplemented with
8 mM Glutamine. Additionally, HyClone Boost 6 supplement (GE Healthcare) was
added with 10% of the end volume. One week after transfection, supernatant was
harvested by 15-min centrifugation at 1500 × g.
Protein purification. Protein purification was performed depending on the pro-
duction scale in either 24-well filter plate with 0.5 mL resin (10 mL scale) or 1 mL
column on Äkta go (Cytiva), Äkta Pure (Cytiva), or Profina System (BIO-RAD).
MabSelect SuRe or HiTrap Fibro PrismA (Cytiva) was used as resins for Protein A
purification. For His-tag purification of Expi293F, supernatant HisTrap FF Crude
column (Cytiva) and for His-tag purification of insect cell supernatant HisTrap
excel column (Cytiva) was used. All purifications were performed according to the
manufacturer’s manual. Indicated antigens were further purified by SEC by a
16/600 Superdex 200 kDa pg (Cytiva). All antigens, antibodies, and scFv-Fc were
run on Superdex 200 Increase 10/300GL (Cytiva) on Äkta or HPLC (Techlab) on
an AdvanceBio SEC 300 Å 2.7 µm, 7.8 × 300 mm (Agilent) for quality control.
Validation of spike protein binding to ACE2. ACE2 binding to the produced
antigens was confirmed in ELISA and on cells in flow cytometry. For ELISA, 200 ng
ACE2-mFc per well was immobilized on a Costar High binding 96-well plate
(Corning, Costar) at 4 °C overnight. Next, the wells were blocked with 350 µL 2%
MBPST (2% (w/v) milk powder in PBS; 0.05% Tween20) for 1 h at RT and then
washed 3 times with H2O and 0.05% Tween20 (BioTek Instruments, EL405).
Afterwards, the respective antigen was added at the indicated concentrations and
incubated 1 h at RT prior to another 3 times washing step. Finally, the antigen was
detected using mouse-anti-polyHis conjugated with horseradish peroxidase (HRP)
(1:20,000, A7058, Sigma) for His-tagged antigens, goat-anti-mIgG(Fc) conjugated
with HRP (1:42,000, A0168, Sigma) for mFc tagged antigen versions, or goat-anti-
hIgG(Fc) conjugated with HRP (1:70,000, A0170, Sigma) if hFc-tagged antigens
had to be detected. Bound antigens were visualized with tetramethylbenzidine
(TMB) substrate (20 parts TMB solution A (30 mM potassium citrate; 1 % (w/v)
citric acid (pH 4.1)) and 1 part TMB solution B (10 mM TMB; 10% (v/v) acetone;
90% (v/v) ethanol; 80 mM H2O2 (30%)) were mixed). After addition of 1 N H2SO4
to stop the reaction, absorbance at 450 nm with a 620-nm reference wavelength
was measured in an ELISA plate reader (BioTek Instruments, Epoch).
To verify the ACE2–antigen interaction on living cells, Expi293F cells were
transfected according to the protocol above using pCSE2.5-ACE2fl-His and 5%
enhanced green fluorescent protein (GFP) plasmid. The gating strategy is shown in
Supplementary Fig. 3. Two days after transfection, purified S1-S2-His, S1-His, or
RBD-His were labeled using the Monolith NTTM His-Tag Labeling Kit RED-tris-
NTA (Nanotemper) according to the manufacturer’s protocol. Fc-tagged ligand
versions were labeled indirectly by using goat-anti-mFc-APC (1:50, 115-136-071,
Dianova) or mouse anti-hFcγ-APC (1:50, Clone HP6017, Biolegend) antibody. In
all, 100, 50, and 25 nM of antigen were incubated with 5 × 105 ACE2-expressing or
non-transfected Expi293F cells (negative control) 50 min on ice. After two washing
steps, fluorescence was measured in MACSQuant Analyzer (Miltenyi Biotec).
Antibody selection using phage display. The antibody selection was performed
as described previously with modifications73. In brief, for panning procedure, the
antigen was immobilized on a High binding 96-well plate (Corning, Costar). Five
micrograms of S1-hFc (produced in High Five cells) was diluted in carbonate buffer
(50 mM NaHCO3/Na2CO3, pH 9.6) and coated onto the wells at 4 °C overnight.
Next, the wells were blocked with 350 µL 2% MBPST (2% (w/v) milk powder in
PBS; 0.05% Tween20) for 1 h at RT and then washed 3 times with PBST (PBS;
0.05% Tween20). Before adding the libraries to the coated wells, the libraries (5 ×
1010 phage particles) were preincubated with 5 µg of an unrelated scFv-Fc and 2%
MPBST on blocked wells for 1 h at RT, to deprive libraries of human Fc fragment
binders. The libraries were transferred to the antigen-coated wells, incubated for
2 h at RT, and washed 10 times. Bound phage were eluted with 150 µL trypsin
(10 µg/mL) at 37 °C, 30 min and used for the next panning round. The eluted phage
solution was transferred to a 96 deep well plate (Greiner Bio-One, Frickenhausen,
Germany) and incubated with 150 µL E. coli TG1 (OD600= 0.5) first for 30 min at
37 °C, then 30 min at 37 °C and 650 rpm to infect the phage particles. One milliliter
2xYT-GA (1.6% (w/v) Tryptone; 1 % (w/v) Yeast extract; 0.5% (w/v) NaCl (pH
7.0), 100 mM D-Glucose, 100 µg/mL ampicillin) was added and incubated for 1 h at
37 °C and 650 rpm, followed by addition of 1 × 1010 colony-forming units
M13KO7 helper phage. Subsequently, the infected bacteria were incubated for
30 min at 37 °C followed by 30 min at 37 °C and 650 rpm before centrifugation for
10 min at 3220 × g. The supernatant was discarded and the pellet resuspended in
fresh 2xYT-AK (1.6% (w/v) Tryptone; 1 % (w/v) Yeast extract; 0.5% (w/v) NaCl
(pH 7.0), 100 µg/mL ampicillin, 50 µg/mL kanamycin). The antibody phage were
amplified overnight at 30 °C and 650 rpm and used for the next panning round. In
total, four panning rounds were performed. In each round, the stringency of the
washing procedure was increased (20× in panning round 2, 30× in panning round
3, 40× in panning round 4) and the amount of antigen was reduced (2.5 µg in
panning round 2, 1.5 µg in panning round 3, and 1 µg in panning round 4). After
the fourth as well as third panning round, single clones containing plates were used
to select monoclonal antibody clones for the screening ELISA.
Screening of monoclonal recombinant binders using E. coli scFv supernatant.
Soluble antibody fragments (scFv) were produced in 96-well polypropylene MTPs
(U96 PP, Greiner Bio-One) as described before55,73. Briefly, 150 μL 2xYT-GA was
inoculated with the bacteria bearing scFv-expressing phagemids. MTPs were
incubated overnight at 37 °C and 800 rpm in a MTP shaker (Thermoshaker PST-
60HL-4, Lab4You, Berlin, Germany). A volume of 180 μL 2xYT-GA in a PP-MTP
well was inoculated with 20 μL of the overnight culture and grown at 37 °C and
800 rpm for 90 min (approx. OD600 of 0.5). Bacteria were harvested by cen-
trifugation for 10 min at 3220 × g, and the supernatant was discarded. To induce
expression of the antibody genes, the pellets were resuspended in 200 μL 2xYT
supplemented with 100 μg/mL ampicillin and 50 μM isopropyl-beta-D-thiogalacto
pyranoside and incubated at 30 °C and 800 rpm overnight. Bacteria were pelleted
by centrifugation for 20 min at 3220 × g and 4 °C.
For the ELISA, 100 ng of antigen was coated on 96-well MTPs (High binding,
Greiner) in PBS (pH 7.4) overnight at 4 °C. After coating, the wells were blocked
with 2% MPBST for 1 h at RT, followed by three washing steps with H2O and
0.05% Tween20. Supernatants containing secreted monoclonal scFv were mixed
with 2% MPBST (1:2) and incubated onto the antigen-coated plates for 1 h at 37 °C
followed by three H2O and 0.05% Tween20 washing cycles. Bound scFv were
detected using murine mAb 9E10, which recognizes the C-terminal c-myc tag (1:50
diluted in 2% MPBST) and a goat anti-mouse serum conjugated with HRP (A0168,
Sigma) (1:42,000 dilution in 2% MPBST). Bound antibodies were visualized with
TMB substrate (20 parts TMB solution A (30 mM potassium citrate; 1% (w/v) citric
acid (pH 4.1)) and 1 part TMB solution B (10 mM TMB; 10% (v/v) acetone; 90%
(v/v) ethanol; 80 mM H2O2 (30%)) were mixed). After stopping the reaction by
addition of 1 N H2SO4, absorbance at 450 nm with a 620-nm reference was
measured in an ELISA plate reader (Epoch, BioTek). Monoclonal binders were
sequenced and analyzed using VBASE2 (www.vbase2.org)74, and possible
glycosylation positions in the CDRS were analyzed according to Lu et al.75.
Inhibition of S1-S2 binding to ACE2 expressing cells using MacsQuant. The
inhibition tests in cytometer on Expi293F cells were performed based on the
protocol for “validation of spike protein binding to ACE2” (see above) but only
binding to S1-S2-His and RBD-mFc antigen (High Five cell produced) was ana-
lyzed. The assay was done in two set-ups. In the first set-up, 50 nM antigen was
incubated with min. 1 µM of different scFv-Fc and the ACE2-expressing cells. The
resulting median antigen fluorescence of GFP-positive living single cells was
measured. For comparison of the different scFv-Fc, first the median fluorescence
background of cells without antigen was subtracted, second it was normalized to
the antigen signal where no antibody was applied. All scFv-Fc showing an inhi-
bition in this set-up were further analyzed by titration (max. 1500–4.7 nM) on S1-
S2-His (High Five cell produced), respectively, on RBD-mFc (max. 100–0.03 nM).
The IC50 was calculated using the equation f(x)=Amin+ (Amax−Amin)/
(1+ (x0/x)^h)^s and parameters from Origin Pro 2019. In addition, pairwise
combinations (max. 750 nM of each scFv-Fc) of the different inhibiting scFv-Fc
were tested.
Dose-dependent binding of the antibodies (scFv-Fc or IgG format) in titration
ELISA. ELISA were essentially performed as described above in “Screening of
monoclonal recombinant binders using E. coli scFv supernatant.” For titration
ELISA, the purified scFv-hFc were titrated from 3.18 µg/mL–0.001 ng/mL on 30 ng/
well of the following antigens: S1-S2-His (High Five cell produced), RBD-mFc
(High Five cell produced), S1-mFc (High Five cell produced), and TUN219-2C1-
mFc (as control for unspecific Fc binding). In addition, all scFv-hFc were also
tested only at the highest concentration (3.18 µg/mL) for unspecific cross-reactivity
on Expi293F cell lysate (104 cells/well), bovine serum albumin (BSA; 1% w/v), and
lysozyme. ScFv-hFc or IgG were detected using goat-anti-hIgG(Fc)-HRP (1:70,000,
A0170, Sigma). Titration assays were performed using 384-well MTPs (Greiner)
using Precision XS microplate sample processor (BioTek), EL406 washer dispenser
(BioTek), and BioStack Microplate stacker (BioTek). EC50 were calculated with
GraphPad Prism Version 6.1, fitting to a four-parameter logistic curve. The binding
of antibodies to S1 subunit His-tagged constructs containing mutations in the RBD
region and the cross-reactivity to spike proteins of other coronaviruses was tested
as described above. S1-HIS proteins from SARS-CoV-2 (expressed in HEK cells),
SARS-CoV-1, MERS, HCoV HKU1, HCoV NL63, and HCoV 229E were acquired
commercially (Sino Biologicals products 40591-V08H, 40150-V08B1, 40069-V08H,
40021-V08H, 40601-V08H, 40600-V08H).
SARS-CoV-2 neutralization in cell culture. VeroE6 cells (ATCC CRL-1586) were
seeded at a density of 6 × 104/well onto cell culture 96-well plates (Nunc, Cat.
#167008). Two days later, cells reached 100% confluence. For neutralization,
antibodies (1 µg/mL final concentration) were mixed with the virus inoculum
(250 pfu/well), using strain SARS-CoV-2/Münster/FI110320/1/2020 (kind gift of
Stephan Ludwig, University of Münster, Germany), in 100 µL full VeroE6 culture
medium (Dulbecco’s modified Eagle’s medium, 10% fetal calf serum, 2 mM glu-
tamine, penicillin, streptomycin) in technical quadruplicates or sixfold replicates
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and incubated for 1 h at 37 °C. Then cells were overlaid with the antibody/virus
mix and phase-contrast images were taken automatically using a Sartorius Incu-
Cyte S3 (×10 objective, 2-h image intervals, 4 images per well) housed in a HeraCell
150i incubator (37 °C, 100% humidity, 5% CO2). Image data were quantified with
the IncuCyte S3 GUI tools measuring the decrease of confluence concomitant with
the CPE of the virus in relation to uninfected controls and controls without
antibody and analyzed with GraphPad Prism 8. Given is the median of the
inhibition.
For titration, antibodies were diluted in 1/√10 steps and mixed with a fixed
inoculum of SARS-CoV-2 (100–150 pfu) in a total volume of 500 µL of Vero E6
medium. After 1 h incubation at 37 °C, cells were infected with the antibody/virus
mix, incubated for 1 h, and then overlaid with Vero E6 medium containing 1.5%
methyl-cellulose. Three days postinfection, wells were imaged using a Sartorius
IncuCyte S3 (×4 objective, whole-well scan) and plaques were counted from these
images.
Cloning and production of IgG. For IgG production, selected antibodies were
converted into the human IgG1 format by subcloning of VH in the vector
pCSEH1c (heavy chain) and VL in the vector pCSL3l/pCSL3k (light chain lambda/
kappa)76, adapted for Golden Gate Assembly procedure with Esp3I restriction
enzyme (New England Biolabs). Expi293F (Thermo Fisher Scientific) cells were
transfected with 12.5 µg of both vectors in parallel in a 1:1 ratio. For production,
the transfected Expi293F cells were cultured in chemically defined medium F17
(Thermo Fisher Scientific) supplemented with 0.1% pluronic F68 (PAN-Biotech)
and 7.5 mM L-glutamine (Merck) for 7 days. A subsequent protein A purification
was performed as described above.
Affinity determination by SPR. The antibody-binding properties were analyzed at
25 °C on a Biacore™ 8 K instrument (GE Healthcare) using 10 mM HEPES pH 7.4,
150 mM NaCl, 3 mM EDTA, and 0.005% Tween-20 as running buffer. SARS-CoV2
RBDs, wild type and different mutants, or full S-protein, were immobilized on the
surface of a CM5 chip through standard amine coupling. Increasing concentration
of antibodies (6.25–12.5–25–50–100 nM) were injected using a single-cycle kinetics
setting and analyte responses were corrected for unspecific binding and buffer
responses. Curve fitting and data analysis were performed with the Biacore™ Insight
Evaluation Software (version 2.0.15.12933).
Analysis of binding to RBD mutants by protein array. Two nanoliters of the
proteins were printed as quadruplicates onto PDITC-coated bScreen slides with a
pitch of 700 µm using a SciFlexArrayer (Scienion AG) in non-contact mode. The
following proteins were spotted on the array: S1-S2, SARS-CoV-2, High5 (this
work); S1, SARS-CoV-2, HEK293 (Sino Biological 40591-V08H); S1, SARS-CoV-2,
Baculovirus (Sino Biological 40591-V08B1); S1-RBD, SARS-CoV-2, HEK293 (Sino
Biological 40592-V08H); S1-humFc, SARS-CoV-2, HEK293 (Sino Biological
40591-V02H); S1S2, SARS-CoV-2, Baculovirus (Sino Biological 40589-V08B1); S2,
SARS-CoV-2, Baculovirus (Sino Biological 40590-V08B); S1-RBD mFc, SARS-
CoV-2, HEK293 (Sino Biological 40592-V05H); S1-RBD32, SARS-CoV-2, High5
(this work); S1-RBD25, SARS-CoV-2, High5 (this work); S1-RBD22, SARS-CoV-2,
High5 (this work); S2, SARS-CoV-2, High5 (this work); S1, SARS-CoV-2, High5
(this work); S1 mFc, SARS-CoV-2, High5 (this work); S1-RBD32 mFc, SARS-CoV-
2, High5 (this work); S1(E484K), SARS-CoV-2, High5 (this work); S1(F486V),
SARS-CoV-2, High5 (this work); S1(N438K), SARS-CoV-2, High5 (this work); S1
(G458R), SARS-CoV-2, High5 (this work); S1S2(D614G), SARS-CoV-2, High5
(this work); S1-RBD(V367F), SARS-CoV-2, HEK293 (Sino Biological 40592-
V08H1); S1-RBD(V483A), SARS-CoV-2, HEK293 (Sino Biological 40592-V08H5);
S1-RBD(R408I), SARS-CoV-2, HEK293 (Acro Biosystems SPD-S52H8); S1-RBD
(G476S), SARS-CoV-2, HEK293 (Acro Biosystems SPD-C52H4); S1-RBD(N354D,
D364Y), SARS-CoV-2, HEK293 (Acro Biosystems SPD-S52H3); S1-RBD(N354D),
SARS-CoV-2, HEK293 (Acro Biosystems SPD-S52H5); S1-RBD(W436R), SARS-
CoV-2, HEK293 (Acro Biosystems SPD-S52H7); S1-RBD, SARS-CoV-2, Baculo-
virus (Sino Biological 40592-V08B); S1(D614G), SARS-CoV-2, HEK293 (Sino
Biological 40591-V08H3); S1-S2, SARS, HEK293 (Acro Biosystems SPN-S52H5);
S1, SARS, HEK293 (Acro Biosystems SIN-S52H5); S1-RBD, SARS, HEK293 (Acro
Biosystems SPD-S52H6); S1-RBD, MERS, Baculovirus (Sino Biological 40071-
V08B1); S1, MERS, HEK293 (Sino Biological 40069-V08H); N, MERS, Baculovirus
(Sino Biological 40068-V08B); S1, HCoV-229E, HEK293 (Acro Biosystems SIN-
V52H4); S1, HCoV-NL63, HEK293 (Acro Biosystems SIN-V52H3); S1, HCoV-
HKU1, HEK293 (Sino Biological 40602-V08H); Streptavidin Cy5 (Thermo Fisher
434316); bBSA, (Thermo Fisher 29130), BSA (Carl Roth GmbH 8076.4). Protein
concentration was adjusted to 200 µg/mL, with the following exceptions: S1-RBD
(E484K) 50 µg/mL, S1-RBD(F486V) 100 µg/mL, S1-RBD(N439K) 138 µg/mL, S1-
RBD(G485R) 91 µg/mL. A bscreen was used for label-free measurement of anti-
body binding to the protein arrays. PBS BSA (1 mg/mL) was used as sample as well
as washing buffer. The flow rate was set to 3 µL/s. The measurement was performed
in 3 steps—first step: blocking solution (50% PBS BSA 1mg/mL, 50% Superblock
(Thermo Scientific—Cat. No.: 37515)); second step: neutralizing SARS-CoV-2
antibody 8 µg/mL; third step: goat anti-human Alexa 546 antibody 5 µg/mL
(Invitrogen—Cat. No.: A-21089). Each step consisted of 150 s baselining, 333 s
association, 300 s dissociation. The label-free signals of the association phase of the
anti-human step were used for data generation. This was done by subtracting the
signal mean value from 30 to 20 s before the association phase from the signal
mean value from 20 to 30 s after the association phase.
Antibody structures and computational docking studies. The antibody struc-
tures were modeled according to the canonical structure method using the
RosettaAntibody program77 as previously described78 and docked to the experi-
mental structure of SARS-CoV-2 S protein RBD (PDBid: 6M17)6.
Docking was performed using the RosettaDock 3.12 software79 as previously
described80. Briefly, each antibody was manually placed with the CDR loops facing
the RBD region containing the residues identified by the peptide mapping
experiment. The two partners were moved away from each other by 25 Å and then
brought together by the computational docking algorithm, obtaining thousands of
computationally generated complexes (typically 15,000). The antibody/RBD
complexes were structurally clustered and then selected according to the scoring
function (an estimate of energetically favorable solutions) and agreement with the
peptide mapping data. Selected complexes were further optimized by a docking
refinement step and molecular dynamics simulations.
The MD simulations were performed using GROMACS81 with standard MD
protocol: antibody/antigen complexes were centered in a triclinic box, 0.2 nm from
the edge, filled with SPCE water model and 0.15M Na+Cl− ions using the
AMBER99SB-ILDN protein force field; energy minimization followed.
Temperature (298 K) and pressure (1 Bar) equilibration steps of 100 ps each were
performed. Five hundred-nanosecond MD simulations was run with the above-
mentioned force field for each protein complexes. MD trajectory files were
analyzed after removal of periodic boundary conditions. The overall stability of
each simulated complex was verified by root mean square deviation, radius of
gyration, and visual analysis according to standard procedures.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that the data supporting the findings of this study are available
within the paper and its supplementary information files. All requests for resources and
reagents should be directed to the Lead Contact author (m.hust@tu-bs.de). This includes
antibodies, plasmids, and proteins. All reagents will be made available on request after
completion of a Material Transfer Agreement. Source data are provided with this paper.
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